Digestive Diseases and Sciences

, Volume 48, Issue 7, pp 1425–1430 | Cite as

Regression of Fibrosis in Chronic Hepatitis C After Therapy with Interferon and Ribavirin

  • Asma Arif
  • Robert A. Levine
  • Schuyler O. Sanderson
  • Leslie Bank
  • Raja P. Velu
  • Ashok Shah
  • Thomas C. Mahl
  • Daniel H. Gregory


Interferon and ribavirin decrease necroinflammation in chronic hepatitis C with or without virological clearance; however, reversibility of fibrosis remains to be established. We evaluated the effect of combination therapy on virological and liver histopathological outcomes in 52 naïve patients and 79 patients unresponsive to interferon monotherapy with predominantly genotype 1 chronic hepatitis C. One hundred four patients completed interferon and ribavirin treatment after 24–48 weeks. Fifty-six paired liver biopsies (mean biopsy interval 28 months) were assessed by the Ishak score. Sustained virological responses were 37% in naïve patients and 22% in re-treated patients. In virological responders and nonresponders, fibrosis and necroinflammation scores decreased by −0.91 (P =0.04) and −0.5 (P =0.02) and by −2.8 (P =0.001) and −0.66 (P =0.06), respectively. Interferon and ribavirin had greater benefit on fibrosis when associated with clearance of HCV RNA. Treatment strategies in virological nonresponders who show fibrosis regression should include consideration of maintenance therapy, if such treatment eventually proves to benefit histological outcomes.

Ishak score liver biopsy ALT improvement HCV RNA clearance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shiffman ML: Improvement in liver histopathology associated with interferon therapy in patients with chronic hepatitis C. Viral Hepatitis 5:27-43, 1999Google Scholar
  2. 2.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998Google Scholar
  3. 3.
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Craxi A, Ling M-H, Albrecht J: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998Google Scholar
  4. 4.
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN: Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699, 1995Google Scholar
  5. 5.
    Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T: Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C. A dynamic view. Gastroenterology 116:378-386, 1999Google Scholar
  6. 6.
    Shiffman ML, Hoffmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, Mills AS, Garrett C: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117:1164-1172, 1999Google Scholar
  7. 7.
    Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H: Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-α therapy: including quantitative assessment by a morphometric method. J Gastroenterol 35:105-111, 2000Google Scholar
  8. 8.
    Lindsay KL, Trepo C, Goodman ZD, Albrecht JK: Improvement in hepatic fibrosis in HCV patients who relapse or do not respond to PEG-IFN a2b (PEG-Intron). Hepatology 32:360A, 2000Google Scholar
  9. 9.
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling M-H, Albrecht J: Impact of pegylated interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313, 2002Google Scholar
  10. 10.
    Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-1137, 2000Google Scholar
  11. 11.
    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517-524, 2000Google Scholar
  12. 12.
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR: Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon. Hepatology 33:704-707, 2001Google Scholar
  13. 13.
    Arthur MJP: Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122:1525-1528, 2002Google Scholar
  14. 14.
    Cheng SJ, Bonis PAL, Lau J, Pham NQ, Wong JB: Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta analysis of controlled and uncontrolled trials. Hepatology 33:231-240, 2001Google Scholar
  15. 15.
    Barbaro G, Di Lorezo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B: Interferon alfa-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 93:2445-2451, 1998.Google Scholar
  16. 16.
    Saracco G, Cianco A, Olivero A: A randomized 4 arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 34:133-138, 2001Google Scholar
  17. 17.
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998Google Scholar
  18. 18.
    Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J: Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31:211-218, 2000Google Scholar
  19. 19.
    Shiffman ML, Hoffmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, Sanyal AJ, Mills AS, Garrett CT: Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. {Hepatology} 26:780-785, 1997Google Scholar
  20. 20.
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterology 97(10):2614-2618, 2002Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • Asma Arif
  • Robert A. Levine
  • Schuyler O. Sanderson
  • Leslie Bank
  • Raja P. Velu
  • Ashok Shah
  • Thomas C. Mahl
  • Daniel H. Gregory

There are no affiliations available

Personalised recommendations